logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

STANCHART (02888) repurchased 394,200 shares on October 9 for GBP 8.3859 million.

date
17:53 12/10/2026
avatar
GMT Eight
Standard Chartered (02888) announced that on October 9, 2026, it repurchased 394,200 shares for GBP 8.3859 million; and cancelled 1,115,300 repurchased shares.
STANCHART (02888) announced that on October 9, 2026, it repurchased 394,200 shares for GBP 8.3859 million; and cancelled 1,115,300 repurchased shares.
Related Articles
HK Stock
LONGFOR GROUP (00960) achieved cumulative total contracted sales of RMB 23.14 billion in the first nine months.
HK Stock
DKE (01770): Chen Dandan Resigns as Deputy General Manager, Board Secretary and Joint Company Secretary
HK Stock
LUZHU BIOTECH-B (02480): Recombinant RSV vaccine receives clinical trial approval in China
LONGFOR GROUP (00960) achieved cumulative total contracted sales of RMB 23.14 billion in the first nine months.
HK Stock
DKE (01770): Chen Dandan Resigns as Deputy General Manager, Board Secretary and Joint Company Secretary
HK Stock
LUZHU BIOTECH-B (02480): Recombinant RSV vaccine receives clinical trial approval in China
HK Stock
RECOMMEND
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
icon
25/09/2026
From IT Services to Enterprise AI: What ATGL Must Prove Next
From IT Services to Enterprise AI: What ATGL Must Prove Next
icon
24/09/2026
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
icon
22/09/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.